We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In its first-quarter earnings report, Thousand Oaks, California-based Amgen cited total revenue for the quarter of $5.6 billion, up 2 percent compared to the first quarter of 2017.
Amgen announced final data from its Phase IIIb LIBERTY clinical trial of Aimovig (erenumab), with positive results likely to lead to a blockbuster drug for migraine sufferers.
Novartis has filed its migraine drug erenumab with the EMA, putting it in pole position among a group of pharma companies racing to develop a new class of drugs to treat the debilitating condition.